Hematology-Oncologyinduction therapypediatric ALL
Withholding Two Daunorubicin Doses in Induction Preserves Outcomes and Lowers Fungal Risk in Favorable-Risk Pediatric B-ALL
By MedXY|Dec 8, 2025
In children with favorable B-lineage ALL, omission of two daunorubicin doses late in induction was noninferior for 5-year EFS and OS and associated with fewer invasive fungal infections, supporting reduced anthracycline exposure in selected
